Drugs / D961H
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01159145 | Jul → Sep 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00930215 | Jun → Aug 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03553563 | Jul 2018 → Dec 2022 | duodenal ulcer, gastric ulcer, peptic esophagitis | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02153398 | Jun 2014 → Apr 2016 | Zollinger-Ellison syndrome, duodenal ulcer, gastric ulcer, gastroesophageal reflux disease +1 | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D961H | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01159145 ↗ |
| Route | Oral | “Oral gelatin capsule” NCT00930215 ↗ |